2024

  • Dahm K, Vijayarangakannan P, Wollscheid HP, Schild H, Rajalingam K. Atypical MAPKs in cancer. FEBS J. 2024 Sep 30. doi: 10.1111/febs.17283. Epub ahead of print. PMID: 39348153.
     
  • Perumal N, Yurugi H, Dahm K, Rajalingam K, Grus FH, Pfeiffer N, Manicam C. Proteome landscape and interactome of voltage-gated potassium channel 1.6 (Kv1.6) of the murine ophthalmic artery and neuroretina. Int J Biol Macromol. 2024 Feb;257(Pt 1):128464. doi: 10.1016/j.ijbiomac.2023.128464. Epub 2023 Dec 2. PMID: 38043654.
     
  • Chakraborty D, Romero R, Rajalingam K. Integrate and conquer: pan-cancer proteogenomics uncovers cancer vulnerabilities and therapeutic opportunities. Signal Transduct Target Ther. 2024 Oct 15;9(1):289. doi: 10.1038/s41392-024-02009-6. PMID: 39406750; PMCID: PMC11480369.
     
  • Petros Kechagioglou, Debomita Chakraborty, Camille Dupont, Hajime Yurugi, Ute Distler, Stefan Tenzer, Alexey Chernobrovkin, Kristina Riegel, Julianne Mooz, Mahil Lamber, Volker Dötsch, Stephen Cosenza, Steven Fruchtman, Krishnaraj Rajalingam. Narazaciclib’s differential targets and kinase inhibitory activity contribute to the enhanced inhibition of tumor growth in preclinical models [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO5-24-01.
     
  • Petros Kechagioglou, Camille Dupont, Hajime Yurugi, Alexey Chernobrovkin, Rossana Romero, Rebecca Tweedell, Thirumala-Devi Kanneganti, Stephen Cosenza, Steven M. Fruchtman, Krishnaraj Rajalingam. Rigosertib promotes anti-tumor activity of cancer cells via CETSA revealed novel targets and activates NLRP3-dependent inflammatory responses [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2033.

2023

  • Kirschner F, Arnold-Schild D, Leps C, Łącki MK, Klein M, Chen Y, Ludt A, Marini F, Kücük C, Stein L, Distler U, Sielaff M, Michna T, Riegel K, Rajalingam K, Bopp T, Tenzer S, Schild H. Modulation of cellular transcriptome and proteome composition by azidohomoalanine-implications on click chemistry-based secretome analysis. J Mol Med (Berl). 2023 May 26. 
     
  • Vitale, Ilio et al. “Apoptotic cell death in disease-Current understanding of the NCCD 2023.” Cell death and differentiation vol. 30,5 (2023): 1097-1154. 
     
  • Bogucka-Janczi K, Harms G, Coissieux MM, Bentires-Alj M, Thiede B, Rajalingam K. ERK3/MAPK6 dictates CDC42/RAC1 activity and ARP2/3-dependent actin polymerization. Elife. 2023 Apr 14;12:e85167. 

2022

  • Renaud E, Riegel K, Romero R, Suryamohan K, Distler U, Tenzer S, Schad A, Musholt TJ, Rajalingam K. Multiomic analysis of papillary thyroid cancers identifies BAIAP2L1-BRAF fusion and requirement of TRIM25, PDE5A and PKCδ for tumorigenesis. Mol Cancer. 2022 Oct 10;21(1):195
  •  
  • Romero R, Zarzycka A, Preussner M, Fischer F, Hain T, Herrmann JP, Roth K, Keber CU, Suryamohan K, Raifer H, Luu M, Leister H, Bertrams W, Klein M, Shams-Eldin H, Jacob R, Mollenkopf HJ, Rajalingam K, Visekruna A, Steinhoff U. Selected commensals educate the intestinal vascular and immune system for immunocompetence. Microbiome. 2022 Sep 28;10(1):158. 
  •  
  • Chouha, N., H. Abou-Hamdan, H. Yurugi, R. Yoshii, H. Ii, A. Najem, G.E. Ghanem, S. Nakata, K. Rajalingam, Y. Peng, D. Wang, C.G. Nebigil, and L. Desaubry, Development of fluorizoline analogues as prohibitin ligands that modulate C-RAF signaling, p21 expression and melanogenesis. Eur J Med Chem, 2022. 242: p. 114635.
  •  
  • Riegel, K., P. Vijayarangakannan, P. Kechagioglou, K. Bogucka, and K. Rajalingam, Recent advances in targeting protein kinases and pseudokinases in cancer biology. Frontiers in Cell and Developmental Biology, 2022. 10: 942500
  •  
  • Eichler, M., U. Distler, U. Nasrullah, A. Krishnan, M. Kaulich, K. Husnjak, W. Eberhardt, K. Rajalingam, S. Tenzer, J. Pfeilschifter, and G. Imre, The caspase-2 substrate p54nrb exhibits a multifaceted role in tumor cell death susceptibility via gene regulatory functions. Cell Death Dis, 2022. 13(4): p. 386.
  •  
  • Mooz, J., K. Riegel, H. Ps, A. Sadanandam, F. Marini, M. Klein, U. Werner, W. Roth, A. Wilken-Schmitz, I. Tegeder, and K. Rajalingam, ARAF suppresses ERBB3 expression and metastasis in a subset of lung cancers. Sci Adv, 2022. 8(11): p. eabk1538.
  •  
  • Fester, N., E. Zielonka, J. Goldmann, A.S. Frombach, U. Muller-Kuller, N. Gutfreund, K. Riegel, J.G.A. Smits, E. Schleiff, K. Rajalingam, H. Zhou, S. Simm, and V. Dotsch, Enhanced pro-apoptosis gene signature following the activation of TAp63alpha in oocytes upon gamma irradiation. Cell Death Dis 13, 204 (2022).
  •  
  • Stickdorn, J., L. Stein, D. Arnold-Schild, J. Hahlbrock, C. Medina-Montano, J. Bartneck, T. Ziss, E. Montermann, C. Kappel, D. Hobernik, M. Haist, H. Yurugi, M. Raabe, A. Best, K. Rajalingam, M.P. Radsak, S.A. David, K. Koynov, M. Bros, S. Grabbe, H. Schild, and L. Nuhn, Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors. ACS Nano. 2022 Mar 22;16(3):4426-4443
  •  
  • Mu H, Zeng Y, Zhuang Y, Gao W, Zhou Y, Rajalingam K, Zhao W: Patterning of Oncogenic Ras Clustering in Live Cells Using Vertically Aligned Nanostructure Arrays. Nano Lett. 2022, 22, 3, 1007–1016.

2021

  • Riegel, K., Yurugi, H., Schlöder, J., Jonuleit H, Kaulich M, Kirschner F, Arnold-Schild D, Tenzer S, Schild H, Rajalingam K. ERK5 modulates IL-6 secretion and contributes to tumor-induced immune suppression. Cell Death Dis 12, 969 (2021)
     
  • Goranci-Buzhala G, Mariappan A, Ricci-Vitiani L, Josipovic N, Pacioni S, Gottardo M, Ptok J, Schaal H, Callaini G, Rajalingam K, Dynlacht B, Hadian K, Papantonis A, Pallini R, Gopalakrishnan J. Cilium induction triggers differentiation of glioma stem cells. Cell Rep. 2021;36(10):109656.
     
  • Schott K, Majer C, Bulashevska A, Childs L, Schmidt MHH, Rajalingam K, Munder M, Konig R. SAMHD1 in cancer: curse or cure? J Mol Med (Berl). 2021; 100(3): 351-372.
     
  • Mukherjee R, Bhattacharya A, Bojkova D, Mehdipour AR, Shin D, Khan KS, Hei-Yin Cheung H, Wong KB, Ng WL, Cinatl J, Geurink PP, van der Heden van Noort GJ, Rajalingam K, Ciesek S, Hummer G, Dikic I. Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection. J Biol Chem. 2021 Aug;297(2):100925.
     
  • Hahn M, Covarrubias-Pinto A, Herhaus L, Satpathy S, Klann K, Boyle KB, Munch C, Rajalingam K, Randow F, Choudhary C, Dikic I. SIK2 orchestrates actin-dependent host response upon Salmonella infection. Proc Natl Acad Sci U S A. 2021 May 11;118(19):e2024144118.
     
  • Imre G, Krahling V, Eichler M, Trautmann S, Ferreiros N, Aman MJ, Kashanchi F, Rajalingam K, Pohlmann S, Becker S, Heringdorf DMZ, Pfeilschifter J. The sphingosine kinase 1 activator, K6PC-5, attenuates Ebola virus infection. iScience. 2021 Mar 5;24(4):102266.
     
  • Dupont CA, Riegel K, Pompaiah M, Juhl H, Rajalingam K. Druggable genome and precision medicine in cancer: current challenges. FEBS J. 2021 Nov;288(21):6142-6158.

2020

  • Sadanandam A, Bopp T, Dixit S, Knapp DJHF, Emperumal CP, Vergidis P, Rajalingam K, Melcher A, Kannan N. A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients. Cell Death Discov. 2020 Dec 8;6(1):141.
     
  • Bogucka, K., Marini, F., Rosigkeit, S., Schloeder J., Jonuleit H., David K., Schlackow M., Rajalingam K. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis. Cancer Gene Ther. 2021 May;28(5):359-374.
     
  • Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, Schulz L, Widera M, Mehdipour AR, Tascher G, Geurink PP, Wilhelm A, van der Heden van Noort GJ, Ovaa H, Muller S, Knobeloch KP, Rajalingam K, Schulman BA, Cinatl J, Hummer G, Ciesek S, Dikic I. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity.  Nature. 2020 Nov;587(7835):657-662.
     
  • Riegel K, Rajalingam K. The non-linearity of RAF-MEK signaling in dendritic cells. Cell Cycle. 2020 Sep;19(18):2249-2259.
     
  • Yurugi H, Zhuang Y, Siddiqui FA, Liang H, Rosigkeit S, Zeng Y, Abou-Hamdan H, Bockamp E, Zhou Y, Abankwa D, Zhao W, Desaubry L, Rajalingam K. A subset of flavaglines inhibits KRAS nanoclustering and activation. J Cell Sci. 2020 Jun 24;133(12):jcs244111.
     
  • Crawford LJ, Campbell DC, Morgan JJ, Lawson MA, Down JM, Chauhan D, McAvera RM, Morris TC, Hamilton C, Krishnan A, Rajalingam K, Chantry AD, Irvine AE. The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. Oncogene. 2020 Jul;39(27):5001-5014. 
     
  • Bong SM, Bae SH, Song B, Gwak H, Yang SW, Kim S, Nam S, Rajalingam K, Oh SJ, Kim TW, Park S, Jang H, Lee BI. Regulation of mRNA export through API5 and nuclear FGF2 interaction. Nucleic Acids Res. 2020 Jun 19;48(11):6340-6352.
     
  • Krishnan A, Berthelet J, Renaud E, Rosigkeit S, Distler U, Stawiski E, Wang J, Modrusan Z, Fiedler M, Bienz M, Tenzer S, Schad A, Roth W, Thiede B, Seshagiri S, Musholt TJ, Rajalingam K. Proteogenomics analysis unveils a TFG-RET gene fusion and druggable targets in papillary thyroid carcinomas. Nat Commun. 2020 Apr 28;11(1):2056.
  • Bogucka K, Pompaiah M, Marini F, Binder H, Harms G, Kaulich M, Klein M, Michel C, Radsak MP, Rosigkeit S, Grimminger P, Schild H, Rajalingam K. ERK3/MAPK6 controls IL-8 production and chemotaxis. Elife. 2020 Apr 21;9:e52511. 
    ​​​​​​​
  • ​​​​​​​​​​​​​​Wiechmann S, Maisonneuve P, Grebbin BM, Hoffmeister M, Kaulich M, Clevers H, Rajalingam K, Kurinov I, Farin HF, Sicheri F, Ernst A. Conformation-specific inhibitors of activated Ras GTPases reveal limited Ras dependency of patient-derived cancer organoids. J Biol Chem. 2020;295(14):4526-40.
    ​​​​​​​
  • Wang D, Tabti R, Elderwish S, Abou-Hamdan H, Djehal A, Yu P, Yurugi H, Rajalingam K, Nebigil CG, Desaubry L. Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases. Cell Mol Life Sci. 2020 Sep;77(18):3525-3546.

2019

  • Werner A, Pieh D, Echchannaoui H, Rupp J, Rajalingam K, Theobald M, Closs EI, Munder M. Cationic Amino Acid Transporter-1-Mediated Arginine Uptake Is Essential for Chronic Lymphocytic Leukemia Cell Proliferation and Viability. Front Oncol. 2019 Nov 20;9:1268.
     
  • Staubitz JI, Musholt TJ, Schad A, Springer E, Lang H, Rajalingam K, Roth W, Hartmann N. ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma. Cancer Genet. 2019 Oct;238:10-17.
     
  • Visekruna A, Hartmann S, Sillke YR, Glauben R, Fischer F, Raifer H, Mollenkopf H, Bertrams W, Schmeck B, Klein M, Pagenstecher A, Lohoff M, Jacob R, Pabst O, Bland PW, Luu M, Romero R, Siegmund B, Rajalingam K, Steinhoff U. Intestinal development and homeostasis require activation and apoptosis of diet-reactive T cells.  J Clin Invest. 2019 Apr 2;129(5):1972-1983.
     
  • Riegel K, Schloder J, Sobczak M, Jonuleit H, Thiede B, Schild H, Rajalingam K. RAF kinases are stabilized and required for dendritic cell differentiation and function. Cell Death Differ. 2020 Apr;27(4):1300-1315.

2018

  • Staubitz JI, Schad A, Springer E, Rajalingam K, Lang H, Roth W, Hartmann N, Musholt TJ. Novel rearrangements involving the RET gene in papillary thyroidcarcinoma. Cancer Genet. 2019 Jan;230:13-20. 
     
  • Kumaraswamy A, Mamidi A, Desai P, Sivagnanam A, Perumalsamy LR, Ramakrishnan C, Gromiha M, Rajalingam K, Mahalingam S. The non-enzymatic RAS effector RASSF7inhibits oncogenic c-Myc function.  J Biol Chem. 2018 Oct 5;293(40):15691-15705.
     
  • Buehler U, Schulenburg K, Yurugi H, Šolman M, Abankwa D, Ulges A, Tenzer S, Bopp T, Thiede B, Zipp F, Rajalingam K. Targeting prohibitins at the cell surfaceprevents Th17-mediated autoimmunity. EMBO J. 2018 Aug 15;37(16):e99429. 
     
  • Wüstenhagen E, Boukhallouk F, Negwer I, Rajalingam K, Stubenrauch F, Florin L.The Myb-related protein MYPOP is a novel intrinsic host restriction factor ofoncogenic human papillomaviruses. Oncogene. 2018 Nov;37(48):6275-6284. 
     
  • Karthik IP, Desai P, Sukumar S, Dimitrijevic A, Rajalingam K, Mahalingam S.E4BP4/NFIL3 modulates the epigenetically repressed RAS effector RASSF8 functionthrough histone methyltransferases. J Biol Chem. 2018 Apr 13;293(15):5624-5635.
     
  • Imre G, Rajalingam K. Apoptosis inhibitor 5: Role in the inhibition ofcaspase-2. Cell Cycle. 2018;17(4):397-398.